tetano
Editor, Senior Moderator
Biochem Biophys Res Commun. 2014 May 22. pii: S0006-291X(14)00930-9. doi: 10.1016/j.bbrc.2014.05.058. [Epub ahead of print]
Identification of a novel multiple kinase inhibitor with potent antiviral activity against influenza virus by reducing viral polymerase activity.
Sasaki Y1, Kakisaka M1, Chutiwitoonchai N1, Tajima S2, Hikono H3, Saito T3, Aida Y4.
Author information
Abstract
Neuraminidase inhibitors are the only currently available influenza treatment, although resistant viruses to these drugs have already been reported. Thus, new antiviral drugs with novel mechanisms of action are urgently required. In this study, we identified a novel antiviral compound, WV970, through cell-based screening of a 50,000 compound library and subsequent lead optimization. This compound exhibited potent antiviral activity with nanomolar IC50 values against both influenza A and B viruses but not non-influenza RNA viruses. Time-of-addition and indirect immunofluorescence assays indicated that WV970 acted at an early stage of the influenza life cycle, but likely after nuclear entry of viral ribonucleoprotein (vRNP). Further analyses of viral RNA expression and viral polymerase activity indicated that WV970 inhibited vRNP-mediated viral genome replication and transcription. Finally, structure-based virtual screening and comprehensive human kinome screening were used to demonstrate that WV970 acts as a multiple kinase inhibitor, many of which are associated with influenza virus replication. Collectively, these results strongly suggest that WV970 is a promising anti-influenza drug candidate and that several kinases associated with viral replication are promising drug targets.
Copyright ? 2014. Published by Elsevier Inc.
KEYWORDS:
Anti-influenza viral drug, Compound library screening, KINOMEscan, Kinase inhibitor, Target database search, vRNP activity
PMID:
24858693
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/24858693
Identification of a novel multiple kinase inhibitor with potent antiviral activity against influenza virus by reducing viral polymerase activity.
Sasaki Y1, Kakisaka M1, Chutiwitoonchai N1, Tajima S2, Hikono H3, Saito T3, Aida Y4.
Author information
Abstract
Neuraminidase inhibitors are the only currently available influenza treatment, although resistant viruses to these drugs have already been reported. Thus, new antiviral drugs with novel mechanisms of action are urgently required. In this study, we identified a novel antiviral compound, WV970, through cell-based screening of a 50,000 compound library and subsequent lead optimization. This compound exhibited potent antiviral activity with nanomolar IC50 values against both influenza A and B viruses but not non-influenza RNA viruses. Time-of-addition and indirect immunofluorescence assays indicated that WV970 acted at an early stage of the influenza life cycle, but likely after nuclear entry of viral ribonucleoprotein (vRNP). Further analyses of viral RNA expression and viral polymerase activity indicated that WV970 inhibited vRNP-mediated viral genome replication and transcription. Finally, structure-based virtual screening and comprehensive human kinome screening were used to demonstrate that WV970 acts as a multiple kinase inhibitor, many of which are associated with influenza virus replication. Collectively, these results strongly suggest that WV970 is a promising anti-influenza drug candidate and that several kinases associated with viral replication are promising drug targets.
Copyright ? 2014. Published by Elsevier Inc.
KEYWORDS:
Anti-influenza viral drug, Compound library screening, KINOMEscan, Kinase inhibitor, Target database search, vRNP activity
PMID:
24858693
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/24858693